Regulatoriskt pressmeddelande2025-06-25 15:00Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025
Regulatoriskt pressmeddelande2025-06-25 12:00Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market
Regulatoriskt pressmeddelande2025-03-27 15:00Scandion Oncology Announces Results of Annual General Meeting
Regulatoriskt pressmeddelande2025-03-12 12:10Scandion Oncology – Notice convening the Annual General Meeting
Regulatoriskt pressmeddelande2025-02-26 17:40Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks
Regulatoriskt pressmeddelande2025-02-26 17:35Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report
Regulatoriskt pressmeddelande2025-02-26 17:30Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting
Regulatoriskt pressmeddelande2025-01-13 06:00Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer
Regulatoriskt pressmeddelande2024-11-20 16:30Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million
Regulatoriskt pressmeddelande2024-11-14 07:30Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024
Pressmeddelande2024-11-05 16:00Invitation to Scandion Oncology webcast and conference call November 11, 2024
Regulatoriskt pressmeddelande2024-11-04 07:30Scandion Oncology announces the start of the exercise period for warrants of series TO 2
Regulatoriskt pressmeddelande2024-10-31 07:30Correction: Scandion Oncology announces exercise price for warrants of series TO 2
Regulatoriskt pressmeddelande2024-10-30 16:00Scandion Oncology announces exercise price for warrants of series TO 2